iStent gets panel nod
This article was originally published in The Gray Sheet
An FDA advisory panel July 30 offered strong support to an implantable glaucoma treatment up for PMA approval. The Ophthalmic Devices Panel voted 7-1 that the benefits of Glaukos Corp.'s iStent trabecular micro-bypass stent outweigh the risks. The advisors voted by the same margin that they had reasonable assurance the device would be safe, and 6-2 that there was a reasonable assurance of effectiveness. If approved, iStent would be indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure in patients with mild to moderate open-angle glaucoma who are being treated with ocular hypotensive medication. It would be the first shunt-type device indicated for non-refractory glaucoma, according to FDA. The agency and Glaukos agreed to long-term post-approval studies prior to the meeting, and the panel also recommended that a device registry be established
You may also be interested in...
Glaukos will likely have to conduct a new, five-year prospective randomized post-market study for its iStent glaucoma device if FDA approves the product's PMA
As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.
Damage limitation action is expected imminently to try and stem the flow of medtech products being taken off the EU market. And it cannot come quickly enough as evidence continues to mount of the negative fall-out resulting from the way the EU’s new medical device regulations have been, and are being, implemented.